Rabbit Anti-Ryanodine Receptor 1 Polyclonal Antibody

Species Reactivity	Key Applications	Host	Format	Antibody Type
H, M, R	ICC, IHC, WB	Rb	Serum	Polyclonal Antibody

Species Reactivity

Key Applications

Host

Format

Antibody Type

H, M, R

ICC, IHC, WB

Serum

Polyclonal Antibody

Description
Catalogue Number	AB9078
Brand Family	Chemicon®
Trade Name	Chemicon
Description	Anti-Ryanodine Receptor 1 Antibody

Description

Catalogue Number

AB9078

Brand Family

Chemicon®

Trade Name

Chemicon

Description

Anti-Ryanodine Receptor 1 Antibody

Product Information
Format	Serum
Control	Western blot = adult mouse skeletal muscle (adult mouse cardiac muscle will be negative). IHC = adult mouse cerebellum Purkinje cells (adult mouse cerebellum granular cells will be negative).
Presentation	Rabbit serum. Liquid.

Product Information

Format

Serum

Control

Western blot = adult mouse skeletal muscle (adult mouse cardiac muscle will be negative).

IHC = adult mouse cerebellum Purkinje cells (adult mouse cerebellum granular cells will be negative).

Presentation

Rabbit serum. Liquid.

Applications
Application	Anti-Ryanodine Receptor 1 Antibody detects level of Ryanodine Receptor 1 & has been published & validated for use in IC, IH & WB.
Key Applications	Immunocytochemistry Immunohistochemistry Western Blotting
Application Notes	Western blot: 1:1,000 using ECL. The antibody reacts with the 500 kDa Ryanodine Receptor 1 protein. Suggested blocking buffer is 10% normal goat serum (or same host as your secondary antibody), 1% BSA in 0.1M PBS with 0.05% Tween 20. Suggested dilution buffer is 1% normal goat serum (or same host as your secondary antibody), 1% BSA in 0.1M PBS with 0.05% Tween 20. Preferred gel percentage is 4-12% gradient gel. Immunocytochemistry: 1:1,000 Immunohistochemistry: 1:1,000 overnight at 2-8°C using a fluorescently labeled secondary antibody. Suggested fixative is 4% paraformaldehyde in 0.1M PBS (one hour). Suggested permeablization method is 0.05% Triton X-100 in dilution buffer. Suggested blocking buffer is 10% normal goat serum (or same host as your secondary antibody) and 1% BSA in 0.1M PBS. Suggested dilution buffer is 1% normal goat serum (or same host as your secondary antibody) and 1% BSA in 0.1M PBS. Optimal working dilutions must be determined by the end user.

Applications

Application

Anti-Ryanodine Receptor 1 Antibody detects level of Ryanodine Receptor 1 & has been published & validated for use in IC, IH & WB.

Key Applications

Immunocytochemistry
Immunohistochemistry
Western Blotting

Application Notes

Western blot: 1:1,000 using ECL. The antibody reacts with the 500 kDa Ryanodine Receptor 1 protein. Suggested blocking buffer is 10% normal goat serum (or same host as your secondary antibody), 1% BSA in 0.1M PBS with 0.05% Tween 20. Suggested dilution buffer is 1% normal goat serum (or same host as your secondary antibody), 1% BSA in 0.1M PBS with 0.05% Tween 20. Preferred gel percentage is 4-12% gradient gel.

Immunocytochemistry: 1:1,000

Immunohistochemistry: 1:1,000 overnight at 2-8°C using a fluorescently labeled secondary antibody. Suggested fixative is 4% paraformaldehyde in 0.1M PBS (one hour). Suggested permeablization method is 0.05% Triton X-100 in dilution buffer. Suggested blocking buffer is 10% normal goat serum (or same host as your secondary antibody) and 1% BSA in 0.1M PBS. Suggested dilution buffer is 1% normal goat serum (or same host as your secondary antibody) and 1% BSA in 0.1M PBS.

Optimal working dilutions must be determined by the end user.

Biological Information
Immunogen	Synthetic peptide from the variant TM region of human Ryanodine Receptor 1.
Host	Rabbit
Specificity	Ryanodine Receptor 1.
Species Reactivity	Human Mouse Rat
Antibody Type	Polyclonal Antibody
Entrez Gene Number	NM_000540.2 NM_001042723.1
Entrez Gene Summary	This gene encodes a ryanodine receptor found in skeletal muscle. The encoded protein functions as a calcium release channel in the sarcoplasmic reticulum but also serves to connect the sarcoplasmic reticulum and transverse tubule. Mutations in this gene are associated with malignant hyperthermia susceptibility, central core disease, and minicore myopathy with external ophthalmoplegia. Alternatively spliced transcripts encoding different isoforms have been described.
Gene Symbol	RYR1 CCO RyR1 RYR MHS1 RYR-1 SKRR MHS RYDR CCD
UniProt Number	P21817
UniProt Summary	FUNCTION: SwissProt: P21817 # Communication between transverse-tubules and sarcoplasmic reticulum. Contraction of skeletal muscle is triggered by release of calcium ions from SR following depolarization of T-tubules. SIZE: 5038 amino acids; 565176 Da SUBUNIT: Homotetramer (Potential). SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein (Probable). TISSUE SPECIFICITY: Skeletal muscle and brain (cerebellum and hippocampus). DISEASE: SwissProt: P21817 # Defects in RYR1 are a cause of malignant hyperthermia (MH) [MIM:145600]. MH is an autosomal dominant pharmacogenetic disorder of skeletal muscle and is one of the main causes of death due to anesthesia. In susceptible people, an MH episode can be triggered by all commonly used inhalational anesthetics such as halothane and by depolarizing muscle relaxants such as succinylcholine. The clinical features of the myopathy are hyperthermia, accelerated muscle metabolism, contractures, metabolic acidosis, tachycardia and death, if not treated with the postsynaptic muscle relaxant, dantrolene. Susceptibility to MH can be determined with the in vitro contracture test (IVCT): observing the magnitude of contractures induced in strips of muscle tissue by caffeine alone and halothane alone. Patients with normal response are MH normal (MHN), those with abnormal response to caffeine alone or halothane alone are MH equivocal (MHE(C) and MHE(H) respectively). & Defects in RYR1 are a cause of central core disease of muscle (CCD) [MIM:117000]. CCD is an autosomal dominant congenital myopathy. Both clinical and histological variability is observed, but affected individuals typically display hypotonia and proximal muscle weakness in infancy, leading to the delay of motor milestones. The clinical course of the disorder is usually slow or nonprogressive in adulthood, and the severity of the symptoms may vary from normal to significant muscle weakness. Microscopic examination of CCD-affected skeletal muscle reveals a predominance of type I fibers containing amorphous-looking areas (cores) that do not stain with oxidative and phosphorylase histochemical techniques. & Defects in RYR1 are the cause of multiminicore disease with external ophthalmoplegia (MMDO) [MIM:255320]; also known as multicore myopathy with external ophthalmoplegia or minicore myopathy with external ophthalmoplegia. MMD is a clinically heterogeneous neuromuscular disorder. General features include neonatal hypotonia, delayed motor development, and generalized muscle weakness and amyotrophy, which may progress slowly or remain stable. Muscle biopsy shows multiple, poorly circumscribed, short areas of sarcomere disorganization and mitochondria depletion (areas termed minicores) in most muscle fibers. Typically, no dystrophic signs, such as muscle fiber necrosis or regeneration or significant endomysial fibrosis, are present in multiminicore disease. SIMILARITY: SwissProt: P21817 ## Belongs to the ryanodine receptor family. & Contains 3 B30.2/SPRY domains. & Contains 5 MIR domains. MISCELLANEOUS: The calcium release channel is modulated by calcium ions, magnesium ions, ATP and calmodulin. & The calcium release channel activity resides in the C-terminal region while the remaining part of the protein constitutes the 'foot' structure spanning the junctional gap between the SR and the T-tubule. It is possible that the foot structure interacts with the cytoplasmic region of the dihydropyridine receptor. & Ryanodine is an alkaloid that binds to the Ca- release channel in junctional SR and modulates its activity.

Biological Information

Immunogen

Synthetic peptide from the variant TM region of human Ryanodine Receptor 1.

Host

Rabbit

Specificity

Ryanodine Receptor 1.

Species Reactivity

Human
Mouse
Rat

Antibody Type

Polyclonal Antibody

Entrez Gene Number

Entrez Gene Summary

This gene encodes a ryanodine receptor found in skeletal muscle. The encoded protein functions as a calcium release channel in the sarcoplasmic reticulum but also serves to connect the sarcoplasmic reticulum and transverse tubule. Mutations in this gene are associated with malignant hyperthermia susceptibility, central core disease, and minicore myopathy with external ophthalmoplegia. Alternatively spliced transcripts encoding different isoforms have been described.

Gene Symbol

RYR1
CCO
RyR1
RYR
MHS1
RYR-1
SKRR
MHS
RYDR
CCD

UniProt Number

P21817

UniProt Summary

FUNCTION: SwissProt: P21817 # Communication between transverse-tubules and sarcoplasmic reticulum. Contraction of skeletal muscle is triggered by release of calcium ions from SR following depolarization of T-tubules.
SIZE: 5038 amino acids; 565176 Da
SUBUNIT: Homotetramer (Potential).
SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein (Probable).
TISSUE SPECIFICITY: Skeletal muscle and brain (cerebellum and hippocampus).
DISEASE: SwissProt: P21817 # Defects in RYR1 are a cause of malignant hyperthermia (MH) [MIM:145600]. MH is an autosomal dominant pharmacogenetic disorder of skeletal muscle and is one of the main causes of death due to anesthesia. In susceptible people, an MH episode can be triggered by all commonly used inhalational anesthetics such as halothane and by depolarizing muscle relaxants such as succinylcholine. The clinical features of the myopathy are hyperthermia, accelerated muscle metabolism, contractures, metabolic acidosis, tachycardia and death, if not treated with the postsynaptic muscle relaxant, dantrolene. Susceptibility to MH can be determined with the in vitro contracture test (IVCT): observing the magnitude of contractures induced in strips of muscle tissue by caffeine alone and halothane alone. Patients with normal response are MH normal (MHN), those with abnormal response to caffeine alone or halothane alone are MH equivocal (MHE(C) and MHE(H) respectively). & Defects in RYR1 are a cause of central core disease of muscle (CCD) [MIM:117000]. CCD is an autosomal dominant congenital myopathy. Both clinical and histological variability is observed, but affected individuals typically display hypotonia and proximal muscle weakness in infancy, leading to the delay of motor milestones. The clinical course of the disorder is usually slow or nonprogressive in adulthood, and the severity of the symptoms may vary from normal to significant muscle weakness. Microscopic examination of CCD-affected skeletal muscle reveals a predominance of type I fibers containing amorphous-looking areas (cores) that do not stain with oxidative and phosphorylase histochemical techniques. & Defects in RYR1 are the cause of multiminicore disease with external ophthalmoplegia (MMDO) [MIM:255320]; also known as multicore myopathy with external ophthalmoplegia or minicore myopathy with external ophthalmoplegia. MMD is a clinically heterogeneous neuromuscular disorder. General features include neonatal hypotonia, delayed motor development, and generalized muscle weakness and amyotrophy, which may progress slowly or remain stable. Muscle biopsy shows multiple, poorly circumscribed, short areas of sarcomere disorganization and mitochondria depletion (areas termed minicores) in most muscle fibers. Typically, no dystrophic signs, such as muscle fiber necrosis or regeneration or significant endomysial fibrosis, are present in multiminicore disease.
SIMILARITY: SwissProt: P21817 ## Belongs to the ryanodine receptor family. & Contains 3 B30.2/SPRY domains. & Contains 5 MIR domains.
MISCELLANEOUS: The calcium release channel is modulated by calcium ions, magnesium ions, ATP and calmodulin. & The calcium release channel activity resides in the C-terminal region while the remaining part of the protein constitutes the 'foot' structure spanning the junctional gap between the SR and the T-tubule. It is possible that the foot structure interacts with the cytoplasmic region of the dihydropyridine receptor. & Ryanodine is an alkaloid that binds to the Ca- release channel in junctional SR and modulates its activity.

Product Usage Statements
Usage Statement	Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Product Usage Statements

Usage Statement

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage and Shipping Information
Storage Conditions	Maintain at -20°C in undiluted aliquots for up to 6 months after date of receipt. Avoid repeated freeze/thaw cycles.

Storage and Shipping Information

Storage Conditions

Maintain at -20°C in undiluted aliquots for up to 6 months after date of receipt. Avoid repeated freeze/thaw cycles.

Packaging Information
Material Size	100 µL

Packaging Information

Material Size

100 µL

实验耗材

分子生物学试剂

蛋白与免疫学

生化试剂

细胞及检测试剂

色谱及层析

仪器设备

实验服务

办公用品

Rabbit Anti-Ryanodine Receptor 1 Polyclonal Antibody

浏览了该商品的用户最终购买

浏览了该商品的用户还浏览了

特卖

重要规格表

我要咨询